Search Results - "Lusher, J M"

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) by CHITLUR, M., WARRIER, I., RAJPURKAR, M., LUSHER, J. M.

“…Haemophilia B is an X‐linked disorder resulting in coagulation factor IX deficiency. Patients with severe deficiency (<1% factor IX activity) may have…”
Get full text

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis by White, 2nd, G C, Rosendaal, F, Aledort, L M, Lusher, J M, Rothschild, C, Ingerslev, J

Get more information

Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse : the saga continues by LUSHER, J. M, CHANDLER, C, BALL, D

Get full text

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A by Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L.

“…Background: B‐domain‐deleted recombinant factor VIII (BDDrFVIII) was developed when the B‐domain was found to be redundant for maintaining haemostasis. This…”
Get full text

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study by Kessler, C. M., Gill, J. C., White II, G. C., Shapiro, A., Arkin, S., Roth, D. A., Meng, X., Lusher, J. M.

“…Background:  Deletion of the B‐domain of recombinant blood coagulation factor VIII (BDDrFVIII) increases the manufacturing yield of the product but does not…”
Get full text

The overall effectiveness of prophylaxis in severe haemophilia by Panicker, J., Warrier, I., Thomas, R., Lusher, J. M.

“…The aim of this retrospective review was to assess the overall effectiveness of prophylaxis when compared with on‐demand treatment of haemophilic patients…”
Get full text

Intracranial and extracranial hemorrhages in newborns with hemophilia : A review of the literature by KULKARNI, R, LUSHER, J. M

“…Intracranial hemorrhage (ICH) and extracranial hemorrhage (ECH) in newborns with hemophilia were reviewed with respect to incidence, anatomic location,…”
Get full text

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors by Key, N S, Aledort, L M, Beardsley, D, Cooper, H A, Davignon, G, Ewenstein, B M, Gilchrist, G S, Gill, J C, Glader, B, Hoots, W K, Kisker, C T, Lusher, J M, Rosenfield, C G, Shapiro, A D, Smith, H, Taft, E

“…To assess the safety and efficacy of a fixed dose of recombinant activated factor VII (rFVIIa; NovoSeven) in the home setting for mild to moderately severe…”
Get more information

Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII by Lusher, J M

“…In hemophiliacs without inhibitors, response to treatment for joint and soft tissue bleeding is much more effective when factor VIII is given early. The same…”
Get more information

Is the incidence and prevalence of inhibitors greater with recombinant products? No by Lusher, J. M.

Get full text

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System by Kulkarni, R., Presley, R. J., Lusher, J. M., Shapiro, A. D., Gill, J. C., Manco‐Johnson, M., Koerper, M. A., Abshire, T. C., DiMichele, D., Hoots, W. K., Mathew, P., Nugent, D. J., Geraghty, S., Evatt, B. L., Soucie, J. M.

“…Aim To describe the prevalence and complications in babies ≤2 years with haemophilia. Methods We used a standardized collection tool to obtain consented data…”
Get full text

Development and introduction of recombinant factor VIII - a clinician's experience by LUSHER, J. M.

Get full text

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update by Lusher, J. M., Roth, D. A.

Get full text

Screening and diagnosis of coagulation disorders by Lusher, Jeanne M.

“…After clinical assessment, pertinent history, and family history, the clinician often has a good idea concerning the cause of a patient's bleeding. The most…”
Get full text

Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: A White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA by KULKARNI, R., PONDER, K. P., JAMES, A. H., SOUCIE, J. M., KOERPER, M., HOOTS, W. K., LUSHER, J. M.

“…Haemophilia and inherited bleeding disorders in newborns and their carrier mothers pose unique challenges. The pattern of bleeding and the causes and risk…”
Get full text

Inhibitor antibodies to factor VIII and factor IX: management by Lusher, J M

“…Inhibitor antibodies directed against factor VIII or factor IX present challenges to the clinician. Fortunately, several management options are available,…”
Get more information

Systemic causes of excessive uterine bleeding by Lusher, J M

“…In assessing a patient with excessive uterine bleeding, the clinician should consider systemic causes in the differential diagnosis. Both hereditary and…”
Get more information

Inhibitor Development in Prospective Clinical Trials with Recombinant Factor VIII Preparations in Previously Untreated Patients by Lusher, Jeanne M.

Get full text

Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors by Unuvar, A., Warrier, I., Lusher, J. M.

“…The development of an inhibitor to transfused factor VIII (FVIII) is a serious treatment‐related problem in haemophiliac children. The management of patients…”
Get full text

Factor IX inhibitors and anaphylaxis in hemophilia B by WARRIER, I, EWENSTEIN, B. M, KATZ, J, BERGMANN, F, LJUNG, R, PETRINI, P, LUSHER, J. M, KOERPER, M. A, SHAPIRO, A, KEY, N, DIMICHELE, D, MILLER, R. T, PASI, J, RIVARD, G. E, SOMMER, S. S

“…We present clinical and laboratory data on 18 children from 12 hemophilia treatment centers in the United States, Canada, and Europe with the purpose of…”
Get full text